Epstein-Barr virus-driven lymphoproliferative disorder post-CAMPATH-1H (alemtuzumab) in refractory polymyositis

Rheumatology

Volumn 50, Issue 4, 2011, Pages 810-812

  Cooles, Faye A H ^a,b   Jackson, Graham H ^b   Menon, Geetha ^b   Isaacs, John D ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; PREDNISOLONE;

ADULT; CASE REPORT; EPSTEIN BARR VIRUS; HUMAN; HUMAN TISSUE; LABORATORY TEST; LETTER; LIVER BIOPSY; LYMPHOPROLIFERATIVE DISEASE; MALE; MUSCLE BIOPSY; POLYMYOSITIS; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUTOIMMUNITY; BIOPSY; CYCLOPHOSPHAMIDE; DNA, VIRAL; DOXORUBICIN; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; POLYMYOSITIS; PREDNISONE; REMISSION INDUCTION; TREATMENT OUTCOME; VINCRISTINE;

EID: 79952795123     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq429     Document Type: Letter

References (10)

1. Thomspson B, Corris P, Miller JA, Cooper RG, Halsey JP, Isaacs JD. Alemtuzumab (Campath-1H) for treatment of refractory polymyositis. J Rheumatol 2008;35:2080-2.
2. Bakker NA, Van Imhoff GW. Post-transplant haemoproliferative disorders from treatment to early detection and prevention? Haematologica 2007;92: 1147-50.
3. Hale G, Waldmann H. Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH users. Blood 1998;91:3079-83.
4. Scheinberg P, Fischer SH, Li L et al. Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anaemia. Blood 2007;109:3219-24.
5. + T lymphocytes after partially depleted allogenic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood 2003;101:4290-7.
6. Jones RJ, Seaman WT, Feng WH et al. Roles of lytic viral activation and IL-6 in early versus late passage lymphoblastoid cell lines and EBV-associated lymphoproliferative disease. Int J Cancer 2007;121: 1274-81.
7. McQueen FM, Dalbeth N. Will Jill come tumbling after? The case for a JAK2-type mutation as a prequel to the connective tissue disorders. N Med Hypotheses 2009;73:651-4.
8. Roch N, Salamerie D, Gressin R et al. Fatal adenoviral and enteroviral and an Epstein-Barr virus positive large B-Cell lymphoma after alemtuzumab treatment in a patient with refractory Sezary syndrome. Scand J Infect Dis 2008;40: 342-6.
9. Kluim-Nelermans HC, Coenen JL, Boers JE, van Imhoff GW, Rosati S. EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. Blood 2008;112: 1039-41.
10. Ghobrial IM, Otterman LA, White WL. An EBV-positive disorder after therapy with Alemtuzumab. N Engl J Med 2003;349:2570-2.